menu
    • menu

    Company profile for Elucida Oncology

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Elucida Oncology, Inc.™ is a biotechnology company focused on the development of life-changing therapeutics based on C’Dots, our novel, ultra-small cancer drug delivery platform. C’Dot-Drug-Conjugates, or CDC’s, are novel therapeutics that can substantially increase the concentration of highly potent cytotoxic drugs inside difficult to treat tumors with reduced systemic exposure due to their unique Target or Clear prop...
    Elucida Oncology, Inc.™ is a biotechnology company focused on the development of life-changing therapeutics based on C’Dots, our novel, ultra-small cancer drug delivery platform. C’Dot-Drug-Conjugates, or CDC’s, are novel therapeutics that can substantially increase the concentration of highly potent cytotoxic drugs inside difficult to treat tumors with reduced systemic exposure due to their unique Target or Clear properties.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Elucida OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Deer Park Drive, Suite E Monmouth Junction, NJ 08852
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.elucidaoncology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/elucida-oncology-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
    Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference

    15 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/15/2830229/0/en/Elucida-Oncology-to-Present-at-the-Evercore-ISI-2024-Emerging-Biotech-Conference.html

    GLOBENEWSWIRE
    15 Feb 2024
    Share Share
    Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    27 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/27/2801510/0/en/Elucida-Oncology-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    27 Dec 2023
    Share Share
    Elucida Oncology Presents Data from Phase 1/2 Study of ELU001
    Elucida Oncology Presents Data from Phase 1/2 Study of ELU001

    23 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/23/2764660/0/en/Elucida-Oncology-Presents-Encouraging-Clinical-Data-from-Phase-1-2-Study-of-ELU001-in-Solid-Tumors-Overexpressing-Folate-Receptor-Alpha-at-ESMO-Congress-2023.html

    GLOBENEWSWIRE
    23 Oct 2023
    Share Share
    Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO
    Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO

    11 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/11/2740945/0/en/Elucida-Oncology-Announces-Abstract-Accepted-for-Poster-Presentation-at-ESMO-Congress-2023.html

    GLOBENEWSWIRE
    11 Sep 2023
    Share Share
    Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
    Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer

    24 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/24/2731387/0/en/Elucida-Oncology-Appoints-Ramzi-Benamar-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    24 Aug 2023
    Share Share
    Elucida Announces First Patient Dosed with ELU001 in Expansion of Ph 1/2 Trial
    Elucida Announces First Patient Dosed with ELU001 in Expansion of Ph 1/2 Trial

    20 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/20/2708440/0/en/Elucida-Oncology-Announces-First-Patient-Dosed-with-ELU001-in-Expansion-Cohort-of-its-Phase-1-2-Clinical-Trial.html

    GLOBENEWSWIRE
    20 Jul 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search